Hoffmann-Vold AM, et al. - In patients with systemic sclerosis (SSc)-related pulmonary arterial hypertension (PAH), authors evaluated the chemokine CCL19–CCL21 axis. For predicting the risk of SSc-related PAH and PAH progression, CCL21 appears to be a promising marker. Findings suggested the probability of CCL21 be part of a dysregulated immune pathway linked to the development of lung vascular damage in SSc. They noted an association of CCL21 with PAH and occurrence of PAH-related events, as seen in multivariate analyses.